These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19522657)

  • 1. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.
    Kumarasamy N; Madhavan V; Venkatesh KK; Saravanan S; Kantor R; Balakrishnan P; Devaleenal B; Poongulali S; Yepthomi T; Solomon S; Mayer KH; Benson C; Schooley R
    Clin Infect Dis; 2009 Jul; 49(2):306-9. PubMed ID: 19522657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
    J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Drug Resistance Testing in a Resource Limited Setting with High Viral Diversity: The First Twenty Eight Months Experience.
    Ngo-Malabo ET; Ngoupo PA; Sadeuh-Mba SA; Akongnwi E; Banaï R; Ngono L; Bilong-Bilong CF; Kfutwah A; Njouom R
    Curr HIV Res; 2017; 15(4):297-305. PubMed ID: 28745207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.
    Wallis CL; Mellors JW; Venter WD; Sanne I; Stevens W
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):480-4. PubMed ID: 19801944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
    Seu L; Mulenga LB; Siwingwa M; Sikazwe I; Lambwe N; Guffey MB; Chi BH
    J Med Virol; 2015 Jul; 87(7):1149-57. PubMed ID: 25754408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
    Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
    Sigaloff KC; Kayiwa J; Musiime V; Calis JC; Kaudha E; Mukuye A; Matama C; Nankya I; Nakatudde L; Dekker JT; Hamers RL; Mugyenyi P; Rinke De Wit TF; Kityo C
    AIDS Res Hum Retroviruses; 2013 Jun; 29(6):925-30. PubMed ID: 23517497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
    Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.
    Reynolds SJ; Laeyendecker O; Nakigozi G; Gallant JE; Huang W; Hudelson SE; Quinn TC; Newell K; Serwadda D; Gray RH; Wawer MJ; Eshleman SH
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1739-44. PubMed ID: 22443282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
    Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
    J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line antiretroviral therapy failure and characterization of HIV-1 drug resistance patterns in children in Mali.
    Sylla M; Dolo O; Maiga AI; Traore FT; Coulibaly YA; Togo J; Fofana DB; Dicko-Traore F; Doumbia S; Orsega S; Diallo S; Murphy RL; Calvez V; Marcelin AG
    Arch Pediatr; 2019 Jul; 26(5):254-258. PubMed ID: 31307909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.
    Hosseinipour MC; Gupta RK; Van Zyl G; Eron JJ; Nachega JB
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S49-56. PubMed ID: 23687289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials.
    Gupta R; Hill A; Sawyer AW; Pillay D
    Clin Infect Dis; 2008 Sep; 47(5):712-22. PubMed ID: 18662137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Prevalence of Drug Resistance Mutations Among Patients Failing First-Line Antiretroviral Therapy and Predictors of Virological Response 24 Weeks After Switch to Second-Line Therapy in São Paulo State, Brazil.
    Matsuda EM; Coelho LPO; Romero GF; de Moraes MJ; Lopez-Lopes GIS; Morejon K; Campeas AE; Cabral GB; Brígido LFM
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):156-164. PubMed ID: 28969448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.